SNORA53: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Target Name: SNORA53

NCBI ID: G677832

SNORA53

Other Name(s): small nucleolar RNA, H/ACA box 53 | Small nucleolar RNA, H/ACA box 53 | ACA53

SNORA53: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Introduction

Small nucleolar RNA (snRNA) is a class of non-coding RNAs that play critical roles in various cellular processes, including DNA replication, gene expression, and RNA splicing. H/ACA box 53 (SNORA53) is a specific snRNA that has been identified as a potential drug target or biomarker. This article will review the structure, function, drug targets and potential applications of SNORA53.

Structure of SNORA53

SNORA53 is a 292-nucleotide snRNA whose most striking feature is its H/ACA box. The H/ACA box is a conserved DNA-binding region that typically contains an 伪-helix and two 尾-hydrogen bonds. The H/ACA box of SNORA53 consists of 19 nucleotides, including two stop codons (UAA and UAG).

Function of SNORA53

SNORA53 plays multiple biological functions in cells. First, it is one of the major players in rRNA splicing. In the nucleus, rRNA enters the cytoplasm through nuclear pores and combines with ribosomes to synthesize proteins. In the cytoplasm, rRNA enters the nucleus through nuclear pores and combines with ribosomes to synthesize more proteins. SNORA53 plays a crucial role in rRNA splicing, ensuring that mature mRNA is spliced 鈥嬧?媜ut, thereby ensuring protein synthesis.

Secondly, SNORA53 is involved in regulating DNA replication. During mitosis and amitosis, the location and expression level of SNORA53 will change, thus affecting the progress of DNA replication.

Drug Targeting of SNORA53

SNORA53, as a molecule, has the potential to become a drug target. Because SNORA53 plays multiple roles in cell biology, developing drugs that target SNORA53 may have important therapeutic implications. Currently, a variety of drugs that inhibit SNORA53 expression have entered clinical research, including anti-nucleotide drugs, anti-RNA binding drugs, and anti-microtubule drugs.

Biomarker for SNORA53

SNORA53 can be used as a potential biomarker. Since SNORA53 is expressed in a variety of cancers, it can be used to monitor tumor progression and treatment effects. Some studies have confirmed that the expression level of SNORA53 is positively correlated with tumor invasion and metastasis. Therefore, SNORA53 can be used as a tumor biomarker to predict tumor invasion and metastasis.

Conclusion

SNORA53 is a snRNA with multiple biological functions and can be used as a drug target or biomarker to treat various cancers. Inhibition of SNORA53 may lead to abnormalities in rRNA splicing, thereby affecting protein synthesis and leading to abnormal physiological and biochemical processes in cells and tumors. Therefore, inhibition of SNORA53 may become a promising anti-tumor drug.

Protein Name: Small Nucleolar RNA, H/ACA Box 53

The "SNORA53 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA53 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets